BeiGene

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BeiGene and other ETFs, options, and stocks.

About ONC

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

CEO

John V. Oyler

CEOJohn V. Oyler

Employees

11,000

Employees11,000

Headquarters

Basel, Basel-Landschaft (Basle Country)

HeadquartersBasel, Basel-Landschaft (Basle Country)

Founded

2010

Founded2010

Employees

11,000

Employees11,000

ONC Key Statistics

Market cap

38.79B

Market cap38.79B

Price-Earnings ratio

-180.75

Price-Earnings ratio-180.75

Dividend yield

—

Dividend yield—

Average volume

166.59K

Average volume166.59K

High today

$312.97

High today$312.97

Low today

$307.92

Low today$307.92

Open price

$310.82

Open price$310.82

Volume

141.93K

Volume141.93K

52 Week high

$355.30

52 Week high$355.30

52 Week low

$170.99

52 Week low$170.99

ONC News

TipRanks 5d

BeOne Medicines Advances in Oncology with Promising BG-T187 Study

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

TipRanks 5d

BeOne Medicines Advances in Multiple Myeloma Treatment with Sonrotoclax Study

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

TipRanks 5d

BeOne Medicines Advances CLL Treatment with Promising Phase 3 Study

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

Analyst ratings

89%

of 38 ratings

Buy

89.5%

Hold

7.9%

Sell

2.6%

More ONC News

TipRanks 5d

BeOne Medicines Explores New Frontiers in Cancer Treatment with Tislelizumab Study

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unl...

TipRanks 5d

BeOne Medicines’ BG-C137 Study: A New Frontier in Cancer Treatment

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

TipRanks 5d

BeOne Medicines Advances Cancer Treatment with BG-68501 Study

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

TipRanks 5d

BeOne Medicines’ MORNINGSTAR Study Update: A Potential Game-Changer in Cancer Treatment

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! U...

TipRanks 5d

BeOne Medicines’ Tislelizumab Study: A Potential Game-Changer for MSI-H/dMMR Tumors

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unl...